Neuronetics narrowed its full-year 2026 total revenue guidance to a range of $160 million to $164 million, compared with prior guidance of $160 million to $166 million. The company also raised its gross margin forecast to between 48% and 50%, up from 47% to 49%, and lowered operating expense guidance to $95 million to $100 million from $100 million to $105 million. Second-quarter total revenue rose 9.1% to $41.6 million, with Greenbrook revenue up 16.8% to $26.9 million while NeuroStar revenue dipped 2.7% to $14.7 million. Management highlighted a strategic shift toward broader NeuroStar ownership models, including outright purchase and lease-financed options, which may cause second-half revenue to be choppier but positions the company for sustainable growth in 2027. The company reported a net loss of $3.4 million, or $0.05 per share, and positive adjusted EBITDA of $0.3 million, with total cash of $25 million as of June 30.
Neuronetics IncNarrowed revenue guidance, raised gross margin outlook, and lowered operating expense guidance, indicating improved profitability.
